Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2023.36863 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2023. Verfasst von Malou Bourdeau und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: COVID-19, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Importance Respiratory syncytial virus (RSV) is a leading cause of pediatric hospitalizations.
Objective
To describe the epidemiology and burden of RSV-associated hospitalizations among children and adolescents in Canadian tertiary pediatric hospitals from 2017 to 2022, including changes during the COVID-19 pandemic. Design, Setting, and Participants This cross-sectional study was conducted during 5 RSV seasons (2017-2018 to 2021-2022) at 13 pediatric tertiary care centers from the Canadian Immunization Monitoring Program Active (IMPACT) program. Hospitalized children and adolescents aged 0 to 16 years with laboratory-confirmed RSV infection were included. Main Outcomes and Measures The proportion of all-cause admissions associated with RSV and counts and proportions of RSV hospitalizations with intensive care unit (ICU) admission, prolonged stay (≥7 days), and in-hospital mortality were calculated overall and by season, age group, and region. Seasonality was described using epidemic curves. RSV hospitalizations for 2021-2022 were compared with those in the prepandemic period of 2017-2018 through 2019-2020. Bonferroni corrections were applied to P values to adjust for multiple statistical comparisons.
Results
Among 11 014 RSV-associated hospitalizations in children and adolescents (6035 hospitalizations among male patients [54.8%]; 5488 hospitalizations among patients aged <6 months [49.8%]), 2594 hospitalizations (23.6%) had admission to the ICU, of which 1576 hospitalizations (60.8%) were among children aged less than 6 months. The median (IQR) hospital stay was 4 (2-6) days. The mean (SD) number of RSV-associated hospitalizations during prepandemic seasons was 2522 (88.8) hospitalizations. There were 58 hospitalizations reported in 2020-2021, followed by 3170 hospitalizations in 2021-2022. The proportion of all-cause hospitalizations associated with RSV increased from a mean of 3.2% (95% CI, 3.1%-3.3%) before the pandemic to 4.5% (95% CI, 4.3%-4.6%) in 2021-2022 (difference, 1.3 percentage points; 95% CI, 1.1-1.5 percentage points; corrected P < .001). A significant increase in RSV-associated hospitalizations was found in 2021-2022 for 3 provinces (difference range, 2.5 percentage points; 95% CI, 1.4-3.6 percentage points for Quebec to 2.9 percentage points; 95% CI, 1.4-3.5 percentage points for Alberta; all corrected P < .001). Age, sex, ICU admission, prolonged length of stay, and case fatality rate did not change in 2021-2022 compared with the prepandemic period. Interregional differences in RSV seasonality were accentuated in 2021-2022, with peaks for 1 province in October, 4 provinces in December, and 3 provinces in April, or May. Conclusions and Relevance This study found that the burden of RSV-associated hospitalizations in Canadian pediatric hospitals was substantial, particularly among infants aged less than 6 months, and RSV hospitalizations increased in 2021-2022 compared with the prepandemic period, while severity of illness remained similar. These findings suggest that RSV preventive strategies for infants aged less than 6 months would be associated with decreased RSV disease burden in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pediatrics, McGill University, Montreal, Quebec, Canada.
- Department of Pediatrics, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
- Vaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba, Canada.
- Canadian Center for Vaccinology, IWK Health Center, Dalhousie University, Halifax, Nova Scotia, Canada.
Förderung
- Medical Research Council
Zitieren
APA
Bourdeau, M., Vadlamudi, N. K., Bastien, N., Embree, J., Halperin, S. A., Jadavji, T., Kazmi, K., Langley, J. M., Lebel, M. H., Le Saux, N., Moore, D., Morris, S. K., Pernica, J. M., Robinson, J., Sadarangani, M., Bettinger, J. A., Papenburg, J., & Canadian Immunization Monitoring Program Active (IMPACT) Investigators (2023). Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.36863
Vancouver
Bourdeau M, Vadlamudi NK, Bastien N, Embree J, Halperin SA, Jadavji T, et al. Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.36863
BibTeX
@article{Bourdeau2023,
author = {Bourdeau, Malou and Vadlamudi, Nirma Khatri and Bastien, Nathalie and Embree, Joanne and Halperin, Scott A and Jadavji, Taj and Kazmi, Kescha and Langley, Joanne M and Lebel, Marc H and Le Saux, Nicole and Moore, Dorothy and Morris, Shaun K and Pernica, Jeffrey M and Robinson, Joan and Sadarangani, Manish and Bettinger, Julie A and Papenburg, Jesse and Canadian Immunization Monitoring Program Active (IMPACT) Investigators, Canadian Immunization Monitoring Program Active (IMPACT) Investigators},
title = {Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.36863}
}
EUVIMED